
    
      In this single arm clinical study, enrolled patients, with advanced stage NSCLC and confirmed
      epidermal growth factor receptor (EGFR) mutation, would receive cryotherapy for tumors and
      begin Icotinib, an EGFR tyrosine kinase inhibitor administration thereafter. Progression free
      survival, overall survival and safety wil be observed.
    
  